Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium

The endothelium lines the luminal surface of every blood vessel, allowing it contact with circulating blood elements, as well as the underlying vascular smooth muscle layer. In healthy vessels, the endothelium expresses constitutive forms of nitric oxide synthase (NOSIII) and cyclo‐oxygenase (COX‐1), which produce the vasoactive hormones NO and prostacyclin, respectively. Both NO and prostacyclin relax blood vessels and inhibit platelet activation. The actions of prostacyclin are mediated by cell surface prostacyclin (IP) receptors and/or intracellular peroxisome proliferator‐activated receptors (PPAR)β. The actions of NO are mediated predominately by activation of intracellular guanylyl cyclase, leading to the formation of cGMP. In platelets, the actions of NO and prostacyclin are synergistic, but in vessels their actions are additive. In diseased vessels, inducible forms of NOS (NOSII) and cyclo‐oxygeanse (COX‐2) are expressed in vascular smooth muscle, resulting in the release of large amounts of NO, prostacyclin and prostaglandin E2. The relative contribution of NOSII and COX‐2 to vascular inflammation is still debated, but is likely to result in both protective and damaging responses. The relative contribution of constitutive forms of NOS and COX, as well as interactions between IP, PPARβ and guanylyl cyclase pathways in vessels and platelets, is discussed.

[1]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[2]  M. Hamberg,et al.  Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides , 1976, Nature.

[3]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[4]  J. Bény,et al.  Interaction of bradykinin and des-Arg9-bradykinin with isolated pig coronary arteries: mechanical and electrophysiological events , 1987, Regulatory Peptides.

[5]  J. Vane,et al.  Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Busse,et al.  Differential role of extra‐ and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells , 1988, British journal of pharmacology.

[7]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[8]  A. Weston,et al.  Acetylcholine releases endothelium‐derived hyperpolarizing factor and EDRF from rat blood vessels , 1988, British journal of pharmacology.

[9]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.

[10]  J. Vane,et al.  Mediators and the anti-thrombotic properties of the vascular endothelium. , 1989, Annals of medicine.

[11]  G. Dusting,et al.  Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium , 1990, Nature.

[12]  N. Meanwell,et al.  Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. , 1990, The Journal of pharmacology and experimental therapeutics.

[13]  F. Murad,et al.  Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Vane,et al.  Different patterns of release of endothelium‐derived relaxing factor and prostacyclin , 1992, British journal of pharmacology.

[15]  E. Werner,et al.  Particulate Endothelial Nitric Oxide Synthase: Requirement and Content of Tetrahydrobiopterin, FAD, and FMN , 1993 .

[16]  Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring. , 1993, Journal of medicinal chemistry.

[17]  S. Narumiya,et al.  Cloning and expression of a cDNA for the human prostacyclin receptor , 1994, FEBS letters.

[18]  S. Narumiya,et al.  Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. , 1994, Circulation.

[19]  Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring. , 1994, Drug design and discovery.

[20]  Y. Boie,et al.  Cloning and expression of a cDNA for the human prostanoid IP receptor. , 1994, The Journal of biological chemistry.

[21]  ONO-AP-500-02: a non prostanoid prostaglandin I2 mimetic with inhibitory activity against thromboxane synthase. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.

[22]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[23]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[24]  Roger Fan,et al.  Dynamic activation of endothelial nitric oxide synthase by Hsp90 , 1998, Nature.

[25]  J. Mitchell,et al.  Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapy , 1999, British journal of pharmacology.

[26]  J. Morrow,et al.  Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.

[27]  Margaret S. Wu,et al.  Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects* , 1999, The Journal of Biological Chemistry.

[28]  Y. Boie,et al.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. , 2000, Biochimica et biophysica acta.

[29]  S. Dey,et al.  PPARδ Functions as a Prostacyclin Receptor in Blastocyst Implantation , 2000, Trends in Endocrinology & Metabolism.

[30]  F. Murad,et al.  NO, nitrotyrosine, and cyclic GMP in signal transduction. , 2001, Medical Science Monitor.

[31]  Daniel Metzger,et al.  Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice , 2001, The Journal of cell biology.

[32]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  U. Walter,et al.  Taming platelets with cyclic nucleotides. , 2001, Biochemical pharmacology.

[34]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[35]  J. Salerno,et al.  Nitric oxide synthases: domain structure and alignment in enzyme function and control. , 2003, Frontiers in bioscience : a journal and virtual library.

[36]  T. Willson,et al.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity , 2003 .

[37]  W. Sessa eNOS at a glance , 2004, Journal of Cell Science.

[38]  C. Francis,et al.  Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes , 2004 .

[39]  S. Moncada,et al.  Nitric oxide and the vascular endothelium. , 2006, Handbook of experimental pharmacology.

[40]  Garret A FitzGerald,et al.  Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. , 2006, American journal of respiratory cell and molecular biology.

[41]  D. Bishop-Bailey,et al.  Peroxisome proliferator-activated receptors and inflammation. , 2006, Pharmacology & therapeutics.

[42]  J. Mitchell,et al.  COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs , 2006, Nature Reviews Drug Discovery.

[43]  F. Faraci,et al.  Endothelium-Derived Hyperpolarizing Factor: Where Are We Now? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[44]  J. Pepper,et al.  Stronger inhibition by nonsteroid anti‐inflammatory drugs of cyclooxygenase‐1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  F. Ali,et al.  Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  M. Montagnani,et al.  Endothelin-1: the yin and yang on vascular function. , 2006, Current medicinal chemistry.

[47]  Prostacyclin analogues: prevention of cardiovascular diseases. , 2006, Cardiovascular & hematological agents in medicinal chemistry.

[48]  Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets , 2007, Blood.

[49]  J. Mitchell,et al.  Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. , 2007, American Journal of Physiology. Heart and Circulatory Physiology.

[50]  B. Brüne,et al.  Apoptotic cells induce arginase II in macrophages, thereby attenuating NO production , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  J. Mitchell,et al.  Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. , 2007, The Journal of endocrinology.

[52]  J. Hwa,et al.  Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. , 2007, Prostaglandins & other lipid mediators.

[53]  J. Fruchart Novel peroxisome proliferator activated receptor-alpha agonists. , 2007, The American journal of cardiology.